Savara (SVRA) Capital Expenditures (2010 - 2026)
Savara (SVRA) posted quarterly Capital Expenditures of $54000.0 for Q1 2026, up 1700.0% year-over-year from $3000.0 in Q1 2025, and up 2600.0% quarter-over-quarter from $2000.0 in Q4 2025.
Savara (SVRA) Capital Expenditures (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Capital Expenditures for 17 consecutive years, with $54000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 1700.0% year-over-year to $54000.0; the TTM figure through Mar 2026 stood at $73000.0 (up 305.56% YoY), while the FY2025 annual figure was $22000.0, down 12.0% from the prior year.
- Capital Expenditures advanced to $54000.0 in Q1 2026 per SVRA's latest filing, from $2000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $225000.0 in Q2 2023 and bottomed at -$9000.0 in Q4 2024.
- Historically, Capital Expenditures has averaged $28642.9 across 5 years, with a median of $7000.0 in 2022.
- Annual changes were most pronounced in 2024 — Capital Expenditures plunged 137.5% — and 2026, when it surged 1700.0%.
- Savara's Capital Expenditures stood at $4000.0 in 2022, then soared by 500.0% to $24000.0 in 2023, then slumped by 137.5% to -$9000.0 in 2024, then soared by 122.22% to $2000.0 in 2025, then surged by 2600.0% to $54000.0 in 2026.
- Business Quant data shows SVRA's Capital Expenditures at $54000.0 in Q1 2026, $2000.0 in Q4 2025, and $2000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 222,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 222,000.00 |
| Jun 30, 2026 | 222,000.00 |
| Mar 31, 2026 | 54,000.00 |
| Mar 31, 2026 | 54,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | -9,000.00 |
| Dec 31, 2024 | -9,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 21,000.00 |
| Jun 30, 2024 | 21,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Mar 31, 2024 | 10,000.00 |